What does Brexit mean for bioethics?
By Xavier Symons,
BioEdge
| 06. 25. 2016
It is tempting to provide an alarmist answer to this question. Yet it is wise to avoid the apocalyptic tone of recent media coverage and first to flag what is not going to change in UK biomedical ethics policy.
As highlighted by a post on the Christian Medical Fellowship Blogs, the UK will not (or, at least, not yet) be leaving the Council of Europe (CoE) – this entity does not fall under the auspices of the EU. That the UK will remain in the CoE is significant, as this is the umbrella organisation for what is known as the Committee on Bioethics, an influential policy body that seeks to apply principles outlined in the Convention on Human Rights and Medicine to new issues in medical technology and research.
The European Court on Human Rights also falls within the purview of the CoE. Importantly, The ECHR has handed down significant decisions within the area of conscientious objection in healthcare.
Yet some suggest the Brexit vote may effect disability rights legislation and regulations in the UK. EU directives about...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...